bendamustine hydrochloride has been researched along with Kahler Disease in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (16.47) | 29.6817 |
| 2010's | 57 (67.06) | 24.3611 |
| 2020's | 14 (16.47) | 2.80 |
| Authors | Studies |
|---|---|
| Gogia, A; Gupta, R; Kumar, L; Kumar, S; Malik, PS; Pathak, N; Prasad, CP; Sahoo, RK; Sharma, A | 1 |
| Bashey, A; Brown, S; Holland, HK; Jackson, KC; Morris, LE; Shegda, N; Solh, M; Solomon, SR; Zhang, X | 1 |
| Akhtar, S; Brouwer, R; Drayson, M; Dunn, J; Iqbal, G; Lindsay, J; Ramasamy, K; Schey, S; Stalker, V; Varghese, S | 1 |
| Costa, BA; Mouhieddine, TH; Ortiz, RJ; Richter, J | 1 |
| Ballestrero, A; Calabrese, M; Ceccardi, A; Cuccarolo, P; Dameri, M; Garlaschi, A; Gristina, L; Stabile, M; Tagliafico, A; Valente, I; Zoppoli, G | 1 |
| Fu, CC; Jin, S; Ma, X; Shang, JJ; Wang, J; Wu, DP; Yao, Y | 1 |
| Chu, XX; Deng, XZ; Fan, CB; Hao, HY; Liu, GQ; Ran, XH; Wu, HY; Yuan, CL; Zhong, YP; Zhou, X | 1 |
| Arai, S; Bharadwaj, S; Budde, LE; Dahiya, S; Frank, MJ; Goyal, A; Hosoya, H; Hovanky, V; Htut, M; Janakiram, M; Jensen, A; Latchford, T; Leahy, S; Liu, L; Mei, M; Miklos, D; Muffly, LS; Sahaf, B; Sidana, S | 1 |
| Assal, A; Bhutani, D; Hu, J; Leng, S; Lentzsch, S; Mapara, M; Pan, S; Raza, S; Wei, A | 1 |
| Fiala, MA; Ghobadi, A; Goldsmith, SR; Schroeder, MA; Stockerl-Goldstein, K; Vij, R; Wang, B; Wildes, TM | 1 |
| Dingeldein, G; Goldschmidt, H; Habermehl, C; Knauf, W; Kunz, C; Moehler, T; Raab, MS; Schlag, R; Terzer, T; Walter, S; Welslau, M | 1 |
| Andrea, M; Becker, C; Bill, M; Braunert, L; Edelmann, T; Franke, GN; Grimm, J; Hammerschmidt, D; Hoffmann, FA; Holzhey, T; Holzvogt, B; Holzvogt, M; Jentzsch, M; Platzbecker, U; Pönisch, W; Remane, Y; Scholz, M; Schönfelder-Fricke, U; Schwarz, M; Schwarzer, A; Schwind, S; Wang, SY; Zehrfeld, T | 1 |
| Badillo, M; Chen, W; Feng, L; Graham, V; Jain, P; Lee, HC; Lee, HJ; Lu, R; Manasanch, EE; Oriabure, O; Orlowski, RZ; Wang, ML | 1 |
| Aquino, S; Boccadoro, M; Corradini, P; Einsele, H; Engelhardt, M; Gay, F; Gentili, S; Gramatzki, M; Günther, A; Montefusco, V; Offidani, M; Palumbo, A; Patriarca, F; Pönisch, W; Salvini, M; Schub, N; Sonneveld, P; Spada, S; Straka, C; Wäsch, R | 1 |
| Bergsagel, PL; Chesi, M; Garayoa, M; González-Díaz, M; González-Méndez, L; Gutiérrez, NC; Hernández-García, S; Herrero, AB; López-Iglesias, AA; Martín-Sánchez, M; Mateos, MV; Mehrling, T; Misiewicz-Krzeminska, I; Ocio, EM; Paíno, T; Primo, D; Quwaider, D; San-Miguel, JF; San-Segundo, L | 1 |
| Andrea, M; Beck, J; Becker, C; Bill, M; Edelmann, T; Gläser, D; Heyn, S; Hoffmann, FA; Jentzsch, M; Kragl, B; Kreibich, U; Lange, T; Mohren, M; Mügge, LO; Niederwieser, D; Pönisch, W; Schliwa, T; Schwarzer, A; Schwind, S; Uhlig, J; Winkelmann, C; Zehrfeld, T | 1 |
| Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K | 1 |
| Chao, NJ; Garrett, AH; Gasparetto, C; Green, MM; Kang, Y; Li, Z; Long, GD; McIntyre, JL; Rizzieri, DA; Sivaraj, D | 1 |
| Badiali, S; Billio, A; Cappelletto, PC; Cortelazzo, S; Luminari, S; Marabese, A; Marcheselli, L; Mian, M; Mondello, P; Pascarella, A; Patriarca, F; Pescosta, N; Tagariello, G; Zambello, R | 1 |
| Bacher, U; Betticher, D; Brégy, R; Egger, T; Farag, SA; Jeker, B; Mansouri Taleghani, B; Novak, U; Pabst, T; Prediletto, I; Zander, T | 1 |
| Christos, PJ; Coleman, M; Gergis, U; Gomez-Arteaga, A; Greenberg, JD; Guarneri, D; Hsu, J; Mark, TM; Mayer, SA; Niesvizky, R; Pearse, RN; Phillips, AA; Rossi, A; Shore, TB; van Besien, K | 1 |
| Goldschmidt, H; Kropff, M; Mügge, LO; Pönisch, W | 1 |
| Coleman, M; Gergis, U; Greenberg, J; Mark, TM; Mayer, S; Niesvizky, R; Pearse, R; Reid, W; Shore, T; Van Besien, K | 1 |
| Cai, B; Gao, C; Huang, J; Lee, CK; Liu, B; Lyu, H; Wang, S | 1 |
| Bell, S; Bird, J; Bowcock, S; Cavenagh, J; Cook, G; D'Sa, S; Davies, F; Lai, M; Morgan, G; Owen, R; Pratt, G; Snowden, JA; Yong, K | 1 |
| Huang, B; Li, J; Liu, J; Lu, B; Pan, J; Zheng, D | 1 |
| Al-Ali, HK; Beck, J; Edelmann, T; Hebenstreit, K; Heyn, S; Hoffmann, FA; Jäkel, N; Lange, T; Mohren, M; Niederwieser, D; Pönisch, W; Röhrborn, R; Schmalfeld, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A | 1 |
| Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L | 1 |
| Bossio, S; De Stefano, L; Gentile, M; Granata, T; Lucia, E; Martino, M; Mazzone, C; Morabito, F; Morabito, L; Palummo, A; Recchia, AG; Vigna, E | 1 |
| Adam, Z; Greil, R; Kasparu, H; Leitgeb, C; Linkesch, W; Ludwig, H; Pour, L; Rauch, E; Seebacher, A; Weißmann, A; Zojer, N | 1 |
| Amiot, M; Descamps, G; Le Gouill, S; Lemieux-Blanchard, E; Maïga, S; Moreau, P; Pellat-Deceunynck, C; Surget, S | 1 |
| Lerner, R; Nahi, H; Svedmyr, E | 1 |
| Motlló, C; Oriol, A | 1 |
| Lentzsch, S | 1 |
| Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T | 1 |
| Cavo, M; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT | 1 |
| Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T | 1 |
| Aujesky, D; Oestmann, A | 1 |
| Chim, CS; Wong, KY | 1 |
| Nakaseko, C | 1 |
| Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K | 1 |
| Gertz, MA | 2 |
| Anglaret, B; Avet-Loiseau, H; Banos, A; Benboubker, L; Benramdane, R; Casassus, P; Chaleteix, C; Cony-Makhoul, P; Decaux, O; Dejoie, T; Dib, M; Fitoussi, O; Fontan, J; Garderet, L; Hulin, C; Jardel, H; Kolb, B; Leleu, X; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Pétillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Traullé, C; Vilque, JP | 1 |
| Andriani, A; Baldini, L; Ballanti, S; Baraldi, A; Bongarzoni, V; Califano, C; Derudas, D; Falcone, A; Fragasso, A; Fraticelli, VL; Madonna, E; Mansueto, G; Mele, G; Mussetti, A; Musto, P; Nozza, A; Patriarca, F; Storti, S; Vincelli, D; Zambello, R | 1 |
| Becker, N; Benner, A; Breitkreutz, I; Egerer, G; Goldschmidt, H; Heining, C; Hillengass, J; Ho, AD; Kosely, F; Raab, MS | 1 |
| Brown, SR; Cavenagh, J; Cavet, J; Cook, G; Cook, M; Davies, F; Flanagan, L; Gregory, W; Morgan, G; Morris, C; Orti, G; Schey, S; Sherratt, D; Tillotson, AL; Williams, C; Yong, K | 1 |
| AlAli, HK; Andrea, M; Becker, C; Edelmann, T; Franke, GN; Gutsche, K; Hammerschmidt, D; Heyn, S; Hoffmann, FA; Holzvogt, B; Jentzsch, M; Kreibich, U; Lange, T; Leiblein, S; Niederwieser, D; Plötze, M; Poenisch, W; Reifenrath, K; Schliwa, T; Schwarz, M; Schwarzbach, H; Schwarzer, A; Schwind, S; Vucinic, V; Zehrfeld, T | 1 |
| Gentile, M; Giagnuolo, G; Mendicino, F; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Hänel, M; Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IG; Stöhr, E | 1 |
| Casado, F; de la Fuente, A; de la Rubia, J; Debén, G; Delgado, J; Echeveste, A; Grande, C; Lahuerta, JJ; Loscertales, J; Mateos, MV; Olave, MT; Osorio, S; Peña, A; Peñalver, FJ; Pérez Ceballos, E; Salar, A; Sastre, JL | 1 |
| Birgin, A; Buadi, FK; Duarte, L; Fiala, M; Gertz, MA; Krishnan, A; Kumar, SK; LaPlant, B; Laumann, K; Levy, J; Maharaj, M; Roy, V; Stockerl Goldstein, K; Vij, R; Zimmerman, T | 1 |
| Berardi, M; Biagioli, T; Bosi, A; Brogi, M; Caldini, A; Nozzoli, C; Staderini, M; Terreni, A | 1 |
| Brunetti, G; Cartoni, C; Chisini, M; Finsinger, P; Foà, R; Gentilini, F; Petrucci, MT | 1 |
| Pecherstorfer, M; Zwickl, H; Zwickl-Traxler, E | 1 |
| Console, G; Gentile, M; Martino, M; Messina, G; Molica, S; Morabito, F; Recchia, AG; Tripepi, G; Vincelli, ID | 1 |
| Badiali, S; Bari, A; Cocito, F; Corso, A; Gentile, M; Guarini, A; Marcheselli, L; Marcheselli, R; Mazzone, C; Mele, G; Minoia, C; Morabito, F; Musto, P; Palumbo, A; Pozzi, S; Ria, R; Rivolti, E; Sacchi, S; Vincelli, I | 1 |
| Akkoç, N; Ar, MC; Aydın, Y; Eşkazan, AE; Öngören, Ş; Salihoğlu, A; Soysal, T; Yalnız, FF | 1 |
| Boldt, T; Goldschmidt, H; Haas, A; Hoffmann, FA; Kreibich, U; Niederwieser, D; Pönisch, W; Ritter, U; Rohrberg, R; Rozanski, M; Schirmer, V; Schwalbe, E; Schwarzer, A; Uhlig, J; Zehrfeld, T | 1 |
| Stewart, AK | 1 |
| Bölke, E; Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Michael, M; Neumann, F; Safaian, NN; Zohren, F | 1 |
| Cheson, BD; Dreyling, M; Friedberg, J; Gribben, J; Hoelzer, D; Knop, S; Montillo, M; Moreau, P; Pieper, A; Rummel, M; Wendtner, CM | 1 |
| Fiore, J; Kozyreva, O; May, SK; Tapan, U | 1 |
| Corderoy, S; Hazel, B; Mahmood, S; Ramasamy, K; Schey, S | 1 |
| Hata, H | 1 |
| Banos, A; Caillot, D; Damaj, G; Fitoussi, O; Garidi, R; Hulin, C; Malard, F; Marit, G; Moreau, P; Morineau, N; Royer, B; Stoppa, AM; Tiab, M | 1 |
| Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Hoy, SM | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Gorak, EJ; Gravenor, DS; Kewalramani, T; Mayo, D; Nassir, Y; Noga, SJ; Patel-Donnelly, D; Siegel, RS; Swift, RA; Yellin, O | 1 |
| Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Cheson, BD; Diehl, V | 1 |
| Gandhi, V | 1 |
| Schrijvers, D; Vermorken, JB | 1 |
| Niederwieser, D; Pönisch, W | 1 |
| Cheson, BD | 1 |
| Bremer, K | 1 |
| Einsele, H; Haen, M; Hebart, H; Knop, S; Schwedes, R; Straka, C | 1 |
| Assmann, M; Bittrich, A; Dachselt, K; Freund, M; Friedrich, T; Grobe, N; Harksel, B; Helbig, W; Herold, M; Merkle, K; Mitrou, PS; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Stelzer, E; Subert, R; Wilhelm, G | 1 |
| Baumann, P; Emmerich, B; Gaul, L; Mandl-Weber, S; Schmidmaier, R | 1 |
| Baumann, P; Bumeder, I; Emmerich, B; Meinhardt, G; Schmidmaier, R; Straka, C | 1 |
| Bruns, I; Czibere, A; Fenk, B; Fenk, R; Graef, T; Haas, R; Kobbe, G; Michael, M; Neumann, F; Zohren, F | 1 |
13 review(s) available for bendamustine hydrochloride and Kahler Disease
| Article | Year |
|---|---|
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives.
Topics: Alkylating Agents; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Multiple Myeloma; Receptors, Chimeric Antigen | 2023 |
An old drug with a new future: bendamustine in multiple myeloma.
Topics: Alkylating Agents; Bendamustine Hydrochloride; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Treatment Outcome | 2013 |
[New drugs in the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Drug Synergism; Drugs, Investigational; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Protease Inhibitors; Protein Kinase Inhibitors; Thalidomide | 2014 |
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local | 2015 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
Bendamustine in multiple myeloma.
Topics: Autografts; Bendamustine Hydrochloride; Humans; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning | 2015 |
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide | 2009 |
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds | 2010 |
[Development of novel agents for multiple myeloma; now and the future].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Discovery; Drug Therapy, Combination; Heterocyclic Compounds; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Thalidomide; Vorinostat | 2011 |
Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Retrospective Studies | 2012 |
Metabolism and mechanisms of action of bendamustine: rationales for combination therapies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; DNA Repair; Drug Synergism; G2 Phase; Humans; Immunologic Factors; Multiple Myeloma; Nitrogen Mustard Compounds; S Phase | 2002 |
Phase I studies with bendamustine: an update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Europe; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphopenia; Multiple Myeloma; Nitrogen Mustard Compounds; Research Design | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
27 trial(s) available for bendamustine hydrochloride and Kahler Disease
| Article | Year |
|---|---|
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2022 |
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
Topics: Bendamustine Hydrochloride; Cytarabine; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2022 |
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Renal Insufficiency; Thalidomide | 2022 |
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis | 2020 |
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Progression-Free Survival; Renal Insufficiency; Treatment Outcome | 2020 |
A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Treatment Outcome | 2021 |
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides | 2021 |
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Prospective Studies; Thalidomide | 2017 |
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2019 |
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation, Autologous; Young Adult | 2019 |
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Transplantation Conditioning; Transplantation, Autologous | 2013 |
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Recurrence; Thalidomide | 2013 |
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Survival Analysis | 2014 |
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Pyrazines; Survival Rate | 2015 |
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Survival Rate; Thalidomide | 2015 |
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2015 |
Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Disease-Free Survival; Female; Home Care Services; Humans; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Treatment Outcome | 2016 |
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diarrhea; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Transplantation Conditioning; Treatment Outcome; Vomiting | 2016 |
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Recurrence; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2008 |
Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Thalidomide | 2011 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Recurrence; Thalidomide; Treatment Outcome | 2012 |
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Prospective Studies; Remission Induction; Survival Rate | 2002 |
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2002 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Germany, East; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Quality of Life; Remission Induction; Survival Analysis; Time Factors; Treatment Failure | 2006 |
First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.
Topics: Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy; Simvastatin | 2007 |
45 other study(ies) available for bendamustine hydrochloride and Kahler Disease
| Article | Year |
|---|---|
Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Breast Neoplasms; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence | 2023 |
[Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
[Bendamustine combined with pomalidomide and dexamethasone in relapsed multiple myeloma with extramedullary disease: a multicenter study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Middle Aged; Multiple Myeloma; Prospective Studies | 2023 |
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Topics: B-Cell Maturation Antigen; Bendamustine Hydrochloride; Cell- and Tissue-Based Therapy; Cyclophosphamide; Humans; Immunotherapy, Adoptive; Multiple Myeloma; Receptors, Chimeric Antigen | 2023 |
DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prednisolone; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Predictive Value of Tests; Prednisone; Prognosis; Retrospective Studies; Treatment Outcome | 2021 |
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Benzimidazoles; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; DNA Repair; Histone Deacetylase Inhibitors; Humans; Membrane Potential, Mitochondrial; Mice; Mice, SCID; Mitochondria; Multiple Myeloma | 2017 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom | 2018 |
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Incidence; Kidney; Lymphoma; Male; Multiple Myeloma | 2019 |
[Therapeutic strategies in multiple myeloma: the future role of bendamustine].
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Forecasting; Humans; Multiple Myeloma; Nitrogen Mustard Compounds | 2013 |
Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
Topics: Apoptosis; Bendamustine Hydrochloride; Benzamides; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 2; DNA Damage; DNA Repair; Drug Combinations; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Histones; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Pyridines; S Phase Cell Cycle Checkpoints | 2013 |
United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Proliferation; Drug Administration Schedule; Drug Dosage Calculations; Humans; Induction Chemotherapy; Multiple Myeloma; Plasma Cells; Recurrence; Remission Induction | 2014 |
Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins.
Topics: Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Everolimus; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Sirolimus | 2013 |
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies | 2013 |
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.
Topics: Bendamustine Hydrochloride; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Melphalan; Multiple Myeloma; Nitrogen Mustard Compounds; Reactive Oxygen Species; Signal Transduction; Tumor Suppressor Protein p53 | 2014 |
Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Central Nervous System; Combined Modality Therapy; Drug Therapy, Combination; Fatal Outcome; Gamma Rays; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Thalidomide; Treatment Outcome | 2014 |
Bendamustine: the remedy that came in from the cold.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines | 2014 |
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
[Hyperammonemic encephalopathy in multiple myeloma].
Topics: Alkalosis, Respiratory; Ammonia; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Dyspnea; Fatal Outcome; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Rett Syndrome | 2014 |
Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunoglobulin G; Karyotyping; Male; Middle Aged; Multiple Myeloma; Mutation; Nitrogen Mustard Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; ras Proteins; Recurrence; Signal Transduction; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure | 2015 |
The role of bendamustine in the management of plasma cell myeloma.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Male; Multiple Myeloma | 2015 |
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Treatment Outcome | 2015 |
Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.
Topics: Adult; Aged; Autografts; Bendamustine Hydrochloride; Bone Marrow; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoiesis; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2016 |
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Blood Component Removal; Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2015 |
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Lymphoproliferative Syndrome; Bendamustine Hydrochloride; Consensus Development Conferences as Topic; Disease Management; Humans; Multiple Myeloma; Practice Guidelines as Topic | 2016 |
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Topics: Bence Jones Protein; Bendamustine Hydrochloride; Blood Protein Electrophoresis; Bortezomib; Dexamethasone; Humans; Immunoelectrophoresis; Immunoglobulin G; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Thalidomide | 2016 |
A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Retrospective Studies; Survival Rate | 2017 |
Bendamustine in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hepatitis B virus; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Virus Activation | 2011 |
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cohort Studies; Compassionate Use Trials; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; France; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Recurrence; Time Factors; Treatment Outcome | 2012 |
Bendamustine: inadequate or outdated data.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic | 2012 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Bendamustine in the treatment of hematologic malignancies. Introduction.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds | 2002 |
The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds | 2005 |
Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bendamustine Hydrochloride; Blotting, Western; cdc25 Phosphatases; Cell Cycle Proteins; Cell Proliferation; Checkpoint Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Flow Cytometry; G2 Phase; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Tyrosine | 2008 |
What is the correct philosophy for the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines | 2007 |
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy | 2007 |